Altimmune's Flu Shot Study: What You Need To Know

Altimmune Inc ALT, which develops immunotherapies and vaccines, is seeing its stock surge on 15 times its average volume after the company reported the results of a midstage study of its lead candidate NasoVAX.

What Happened

The nanocap biotech company said Tuesday that additional data from a Phase 2 extension study of its NasoVAX, an intranasal influenza vaccine candidate, showed that 100 percent of the evaluated subjects remained seroprotected.

The seroconversion rate was unchanged more than one year after vaccination, the company said. 

The Phase 2 extension study enlisted the subjects from the highest dose group of the midstage study to evaluate the duration of immunity one year after vaccination.

All eight subjects out of the 15 invited, who returned an average of 13.5 months after vaccination, remained seroprotected.

The study results — along with previously demonstrated mucosal antibody and T-cell related correlates of immunoprotection — underlined NasoVAX's potential as an effective competitor to other flu vaccines under development, the company said.

Why It's Important

Data from a Phase 2 study presented at IDWeek in early October showed that NasoVAX was well-tolerated and elicited comparable antibody responses and nearly sixfold higher cellular immune response than Sanofi SA SNY's Fluzone injectable influenza vaccine.

"We are excited about the continued positive NasoVAX results and believe that if approved, NasoVAX has the potential to capture a significant portion of the global flu vaccine market," Altimmune President and CEO Vipin Garg said in a statement.

What's Next

Following continued positive data, Altimmune said it is seeking development and commercialization partnerships for its NasoVAX program, allowing it leeway to focus on its multiple early- to mid-stage pipeline assets.

"We are currently engaged in a rigorous acquisition review process focused on novel immunotherapeutic approaches for cancer, including immunostimulants and oncolytic viruses, and innovative product candidates for liver diseases," the company said.

Altimmune shares were up 14.88 percent at $3.32 at the close Tuesday. 

Related Links:

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings

Why Dermira Shares Are Shooting Higher After Last Year's Disappointment

Posted In: influenzaVaccinesBiotechNewsHealth CareTop StoriesTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.